Global Community

Willamette Valley Vineyards looks cheap at first glance, but shrinking demand for wine and rising costs are squeezing the business at the worst possible time. The company leans heavily on a complicated financing setup and shows signs of cash strain, which could leave everyday shareholders with little room for upside if things don’t improve.Read more

Lendlease (ASX: LLC) at $2.80 — Cheap Assets, But Is the Return Good Enough? I’ve rebuilt my Lendlease valuation following the FY26 result and stress-tested the original thesis.Read more

AS ONE just put up a record year, but it signals a pause as it spends more on new facilities, logistics, and marketing to fuel the next leg of growth. The key question is whether these investments and a lift in demand for certain consumables can turn into stronger profits in the years ahead.Read more

For more Special Sits ideas, sign up for my free blog TLDR: Jumia trades at ~$6 and I own the January 2028 $7/$15 call spread for $1.15, which pays around 7:1 if this company finally stops burning cash. The last time the stock traded in the mid-teens was in January.Read more

Key Takeaways Oncolytics Biotech is developing one main drug, pelareorep, for hard-to-treat gastrointestinal cancers. The simple idea behind the science is to use a naturally occurring virus to wake up the immune system inside tumors that normally hide from it.Read more

Brightstar is building a new gold processing plant in Western Australia and says it’s fully funded, with a clear path to become a bigger producer once construction and start-up go to plan. The bigger question is whether it can hit its timeline and costs while carrying expensive debt—and whether a second, much larger project can turn today’s exploration success into a real mine.Read more

Sodick says it’s moving from a turnaround to an “on the offensive” growth phase, helped by rising demand tied to data center build-outs and a new multi-year plan focused on growth and shareholder returns. The catch is whether it can hit its profit goals as it ramps up spending and deals, making the next few years a real test of execution.Read more

At $1.40, CNI looks approximately fairly valued to modestly undervalued , rather than obviously cheap. My central intrinsic value is about $1.45–$1.50 per security , with: Scenario Intrinsic value vs $1.40 Severe downside $0.85–$0.95 -32% to -39% Conservative $1.25–$1.35 -4% to -11% Base case $1.45–$1.50 +4% to +7% Good execution $1.70–$1.85 +21% to +32% Bull / AI succeeds $1.90–$2.10+ +36% to +50% The important point is that $1.40 is not the same type of “discount to hard NAV” opportunity that the $1.81 stated NAV might initially suggest.Read more

Disclosure: I do not hold shares in Toll Brothers. Toll Brothers' latest quarter presents a mixed picture.Read more